Company	Indication	Project	Status
Acadia Pharmaceuticals San Diego, CA	Schizophrenia	ACP-104 (des-methylclozapine)	Phase II
Argolyn Biosciences North Charleston, SC	Schizophrenia	ABS-201, a neurotensin analogue	Preclinical Development
Avera Pharmaceuticals San Diego, CA	Schizophrenia	AV965, a serotonin 5-HT1A partial agonist	Phase I
Biovalve Technologies Westborough, MA	Schizophrenia	BT-100, a dopamine D1 receptor agonist	Phase II
Houston Pharma Bellaire, TX	Schizophrenia	Idazoxan, an α2 antagonist	Phase II
Marinus Pharmaceuticals New Haven, CT	Bipolar Disorder and Schizophrenia	Chelerythrine, an inhibitor of protein kinase C	Preclinical Development
Memory Pharmaceuticals Montvale, NJ	Cognitive Deficits in Schizophrenia	MEM 3454, a nicotinic α7 agonist	Phase II
Omeros Seattle, WA	Psychosis	Phosphodiesterase 10 inhibitor	Preclinical Development
Repligen Waltham, MA	Bipolar Depression	Uridine	Phase II

At this time, available SMRI funds are fully committed and new proposals are not being accepted.